{
  "low": {
    "symbol": "JNJ",
    "company_name": "Johnson & Johnson",
    "week_start": "2025-11-26",
    "week_end": "2025-12-03",
    "reasons": [
      "Price performance over the last 5 trading days: about 3.3%.",
      "Measured daily volatility around 0.9%, classified as low risk.",
      "Risk-adjusted model score (momentum minus volatility) gives a relatively attractive profile.",
      "News analysis (AI model, summary across multiple sources):",
      "News sentiment (AI model, FinBERT) based on 2 articles from the last few days.",
      "News summary for JNJ (Johnson & Johnson): Johnson & Johnson (JNJ) shares have edged higher over the past month, building on a steady run that has seen the stock advance 17% in the past 3 months. The share price momentum for Johnson & Johnson has been impressive, with steady gains this year suggesting renewed investor confidence as the company continues to navigate a shifting healthcare landscape."
    ],
    "score": 0.03381943567841067,
    "risk": "low"
  },
  "medium": {
    "symbol": "LLY",
    "company_name": "Eli Lilly and Company",
    "week_start": "2025-11-26",
    "week_end": "2025-12-03",
    "reasons": [
      "Price performance over the last 5 trading days: about 7.8%.",
      "Measured daily volatility around 1.6%, classified as medium risk.",
      "Risk-adjusted model score (momentum minus volatility) gives a relatively attractive profile.",
      "News analysis (AI model, summary across multiple sources):",
      "News sentiment (AI model, FinBERT) based on 8 articles from the last few days.",
      "News summary for LLY (Eli Lilly and Company): Bernstein drops jaw-dropping price target on Eli Lilly stock. US government has negotiated a 71 per cent discount for Novo Nordiskâ€™s weight-loss drugs Ozempic and Wegovy for patients enrolled in Medicare."
    ],
    "score": 0.08757754736721018,
    "risk": "medium"
  },
  "high": {
    "symbol": "MRK",
    "company_name": "Merck & Co. Inc.",
    "week_start": "2025-11-26",
    "week_end": "2025-12-03",
    "reasons": [
      "Price performance over the last 5 trading days: about 9.6%.",
      "Measured daily volatility around 2.1%, classified as high risk.",
      "Risk-adjusted model score (momentum minus volatility) gives a relatively attractive profile.",
      "News analysis (AI model, summary across multiple sources):",
      "News sentiment (AI model, FinBERT) based on 6 articles from the last few days.",
      "News summary for MRK (Merck & Co. Inc.): Merck shares received an upgrade at Wells Fargo, with analyst Mohit Bansa lifting the stock to Overweight and raising the price target to $125 per share. Merck and Qualcomm combine strong cash flow with steady dividend growth, signaling potential for meaningful payout increases ahead."
    ],
    "score": 0.10317084379037977,
    "risk": "high"
  }
}